[{"id":"bf5cc737-c6cb-4899-99a5-c61a24a807ae","acronym":"SJ901","url":"https://clinicaltrials.gov/study/NCT04923126","created_at":"2021-06-11T18:56:10.986Z","updated_at":"2025-02-25T12:37:53.246Z","phase":"Phase 1/2","brief_title":"SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma","source_id_and_acronym":"NCT04923126 - SJ901","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" BRAF • NF1 • PTPN11 • MYBL1","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • NF1 • PTPN11 • MYBL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 06/21/2021","start_date":" 06/21/2021","primary_txt":" Primary completion: 06/01/2031","primary_completion_date":" 06/01/2031","study_txt":" Completion: 06/01/2031","study_completion_date":" 06/01/2031","last_update_posted":"2025-02-24"},{"id":"42d928bf-01a8-4f38-bc3e-dbcbf7fa205e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161974","created_at":"2023-12-08T22:16:35.701Z","updated_at":"2025-02-25T13:41:56.353Z","phase":"Phase 2","brief_title":"Study of Olutasidenib and Temozolomide in HGG","source_id_and_acronym":"NCT06161974","lead_sponsor":"Rigel Pharmaceuticals","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Rezlidhia (olutasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2035","study_completion_date":" 06/01/2035","last_update_posted":"2025-02-21"},{"id":"70012bdf-9a68-4791-98f7-f3a645c2ba06","acronym":"","url":"https://clinicaltrials.gov/study/NCT04295759","created_at":"2021-01-18T20:50:32.592Z","updated_at":"2025-02-25T14:01:55.137Z","phase":"Phase 1","brief_title":"INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas","source_id_and_acronym":"NCT04295759","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" HER-2 • CD4 • ADAM10","pipe":"","alterations":" ","tags":["HER-2 • CD4 • ADAM10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aderbasib (INCB7839)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2025-02-19"},{"id":"94c408ac-7175-4009-9855-94101a5bc215","acronym":"M23-385","url":"https://clinicaltrials.gov/study/NCT05599984","created_at":"2022-10-31T13:56:57.345Z","updated_at":"2025-02-25T14:03:07.565Z","phase":"Phase 1","brief_title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05599984 - M23-385","lead_sponsor":"AbbVie","biomarkers":" EGFR • SEZ6","pipe":" | ","alterations":" EGFR mutation • IDH wild-type","tags":["EGFR • SEZ6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 12/05/2022","start_date":" 12/05/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-19"},{"id":"624dd6dc-cc83-4a6f-bc36-82aa836ef4f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05429502","created_at":"2022-06-23T16:00:07.143Z","updated_at":"2025-02-25T14:08:56.594Z","phase":"Phase 1/2","brief_title":"Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors","source_id_and_acronym":"NCT05429502","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MYCN • SMARCB1","pipe":" | ","alterations":" IDH wild-type","tags":["MYCN • SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Kisqali (ribociclib) • topotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 231","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 10/15/2027","primary_completion_date":" 10/15/2027","study_txt":" Completion: 01/28/2028","study_completion_date":" 01/28/2028","last_update_posted":"2025-02-17"},{"id":"d494a72a-9ff2-45f5-b7e1-6d9a0c5e5875","acronym":"","url":"https://clinicaltrials.gov/study/NCT05503797","created_at":"2022-08-17T14:55:09.900Z","updated_at":"2025-02-25T14:09:04.053Z","phase":"Phase 2","brief_title":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","source_id_and_acronym":"NCT05503797","lead_sponsor":"Fore Biotherapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plixorafenib (FORE-8394) • Tybost (cobicistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/27/2025","primary_completion_date":" 06/27/2025","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-17"},{"id":"22e86fd8-4f8f-4456-992c-88f257edf9a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05345002","created_at":"2022-04-25T21:58:14.873Z","updated_at":"2025-02-25T14:41:19.773Z","phase":"Phase 2","brief_title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","source_id_and_acronym":"NCT05345002","lead_sponsor":"Stephen Bagley, MD, MSCE","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-14"},{"id":"c5be4f65-abfd-49b2-9e6b-92e20f00da7f","acronym":"STING","url":"https://clinicaltrials.gov/study/NCT03048084","created_at":"2021-01-18T15:00:39.333Z","updated_at":"2025-02-25T16:51:48.926Z","phase":"Phase 4","brief_title":"Seizure Treatment in Glioma","source_id_and_acronym":"NCT03048084 - STING","lead_sponsor":"Leiden University Medical Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH wild-type","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-04"},{"id":"b5925ff8-a414-4e5c-8129-fb6140d88f40","acronym":"PNOC028","url":"https://clinicaltrials.gov/study/NCT05887882","created_at":"2024-06-08T04:17:18.068Z","updated_at":"2025-02-25T17:38:54.746Z","phase":"Phase 1","brief_title":"Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors","source_id_and_acronym":"NCT05887882 - PNOC028","lead_sponsor":"Sabine Mueller, MD, PhD","biomarkers":" TGFB1 • TGFBI","pipe":"","alterations":" ","tags":["TGFB1 • TGFBI"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-01-29"},{"id":"254804cf-c50f-409d-b809-0f0a4043dc18","acronym":"CL1-95032-005","url":"https://clinicaltrials.gov/study/NCT05484622","created_at":"2022-08-02T12:55:57.680Z","updated_at":"2025-02-25T16:18:00.683Z","phase":"Phase 1","brief_title":"Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma","source_id_and_acronym":"NCT05484622 - CL1-95032-005","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Voranigo (vorasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 01/20/2023","start_date":" 01/20/2023","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 08/30/2027","study_completion_date":" 08/30/2027","last_update_posted":"2025-01-14"},{"id":"652d0b54-6a18-4c4d-b642-1b099fb25232","acronym":"","url":"https://clinicaltrials.gov/study/NCT02658279","created_at":"2021-01-18T12:56:53.610Z","updated_at":"2025-02-25T16:04:15.191Z","phase":"","brief_title":"Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype","source_id_and_acronym":"NCT02658279","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSI • POLE • MSH6 • MSH2 • POLD1","pipe":"","alterations":" ","tags":["MSI • POLE • MSH6 • MSH2 • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 01/22/2016","start_date":" 01/22/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-12-06"},{"id":"69c0c3d7-d12e-4846-a87b-98d5f38f2dcd","acronym":"SJDAWN","url":"https://clinicaltrials.gov/study/NCT03434262","created_at":"2021-01-18T16:56:26.116Z","updated_at":"2025-02-25T15:54:00.489Z","phase":"Phase 1","brief_title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","source_id_and_acronym":"NCT03434262 - SJDAWN","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 05/24/2024","study_completion_date":" 05/24/2024","last_update_posted":"2024-05-31"},{"id":"87923196-97d9-4e54-a07f-3d2558fab429","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101905","created_at":"2021-01-18T09:41:49.492Z","updated_at":"2024-07-02T16:35:07.246Z","phase":"Phase 1","brief_title":"Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT02101905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 03/13/2014","start_date":" 03/13/2014","primary_txt":" Primary completion: 10/19/2021","primary_completion_date":" 10/19/2021","study_txt":" Completion: 10/19/2024","study_completion_date":" 10/19/2024","last_update_posted":"2024-04-29"},{"id":"ea3578e9-dece-4f8e-8a45-a557cb4ab371","acronym":"","url":"https://clinicaltrials.gov/study/NCT02192359","created_at":"2021-01-18T10:14:16.362Z","updated_at":"2024-07-02T16:35:07.217Z","phase":"Phase 1","brief_title":"Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas","source_id_and_acronym":"NCT02192359","lead_sponsor":"City of Hope Medical Center","biomarkers":" UGT1A1","pipe":"","alterations":" ","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/07/2016","start_date":" 03/07/2016","primary_txt":" Primary completion: 02/21/2022","primary_completion_date":" 02/21/2022","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-04-29"},{"id":"4649ce0f-4d86-452f-8851-2645fe630f89","acronym":"","url":"https://clinicaltrials.gov/study/NCT05592743","created_at":"2022-10-25T13:56:20.154Z","updated_at":"2024-07-02T16:35:07.258Z","phase":"","brief_title":"Vorasidenib Expanded Access Program","source_id_and_acronym":"NCT05592743","lead_sponsor":"Servier","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-04-26"},{"id":"9f4d4138-2575-46b3-8cf6-894603dcfc63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04908176","created_at":"2021-06-01T17:53:25.780Z","updated_at":"2024-07-02T16:35:07.927Z","phase":"Phase 1","brief_title":"A Drug-drug Interaction Study of Avapritinib and Midazolam","source_id_and_acronym":"NCT04908176","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-04-23"},{"id":"84233739-ed53-4cf9-9895-5c8bd3e952d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03043391","created_at":"2021-01-18T14:59:13.296Z","updated_at":"2024-07-02T16:35:10.938Z","phase":"Phase 1","brief_title":"Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children","source_id_and_acronym":"NCT03043391","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 11/07/2017","start_date":" 11/07/2017","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2024-04-08"},{"id":"3dd7c2f3-5edb-4afd-aab6-f0b5ef867dad","acronym":"","url":"https://clinicaltrials.gov/study/NCT03796273","created_at":"2021-01-18T18:46:15.719Z","updated_at":"2024-07-02T16:35:11.784Z","phase":"Phase 1","brief_title":"Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases","source_id_and_acronym":"NCT03796273","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" KDR • CD24 • POU5F1 • VEGFC","pipe":"","alterations":" ","tags":["KDR • CD24 • POU5F1 • VEGFC"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-04-03"},{"id":"ab51b5e6-0963-4336-9f95-fd4b7d31aa37","acronym":"POLO","url":"https://clinicaltrials.gov/study/NCT04702581","created_at":"2021-01-19T20:50:53.653Z","updated_at":"2024-07-02T16:35:14.234Z","phase":"Phase 3","brief_title":"A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery","source_id_and_acronym":"NCT04702581 - POLO","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-03-18"},{"id":"50f8b205-06c7-4e3e-b459-1ebbfce2f273","acronym":"","url":"https://clinicaltrials.gov/study/NCT04910022","created_at":"2021-06-02T20:57:18.421Z","updated_at":"2024-07-02T16:35:14.620Z","phase":"Phase 1/2","brief_title":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT04910022","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" EGFR • IDH1 • IDH2 • MGMT • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • IDH1 • IDH2 • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • itareparib (NMS-293)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-15"},{"id":"caba8d6b-3a99-4cf4-a5f0-d1c3cfbe3575","acronym":"","url":"https://clinicaltrials.gov/study/NCT03343197","created_at":"2021-01-18T16:30:40.675Z","updated_at":"2024-07-02T16:35:17.668Z","phase":"Phase 1","brief_title":"Study of AG-120 and AG-881 in Subjects With Low Grade Glioma","source_id_and_acronym":"NCT03343197","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" ATRX mutation • IDH1 R132H • IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Voranigo (vorasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 08/02/2019","primary_completion_date":" 08/02/2019","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-02-26"},{"id":"77149011-4b82-46a9-addd-cd3261cdd6a7","acronym":"INDIGO","url":"https://clinicaltrials.gov/study/NCT04164901","created_at":"2021-01-18T20:19:25.505Z","updated_at":"2024-07-02T16:35:27.123Z","phase":"Phase 3","brief_title":"Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)","source_id_and_acronym":"NCT04164901 - INDIGO","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 01/05/2020","start_date":" 01/05/2020","primary_txt":" Primary completion: 09/06/2022","primary_completion_date":" 09/06/2022","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2023-12-05"},{"id":"fd91fe18-af69-409c-a905-0f8aee67d795","acronym":"","url":"https://clinicaltrials.gov/study/NCT01130077","created_at":"2021-01-18T04:29:21.248Z","updated_at":"2024-07-02T16:35:30.493Z","phase":"Phase 1","brief_title":"A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas","source_id_and_acronym":"NCT01130077","lead_sponsor":"James Felker","biomarkers":" IFNG","pipe":" | ","alterations":" HLA-A2 positive","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-03"},{"id":"809a0473-89c4-4bc7-8faf-bd2441b7e0a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02549833","created_at":"2021-01-18T12:20:05.485Z","updated_at":"2024-07-02T16:35:34.594Z","phase":"Phase 1","brief_title":"Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma","source_id_and_acronym":"NCT02549833","lead_sponsor":"Jennie Taylor","biomarkers":" CD8 • CXCL10 • CD4","pipe":" | ","alterations":" CXCL10 expression","tags":["CD8 • CXCL10 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCL10 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GBM6-AD • Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/17/2016","start_date":" 10/17/2016","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-10-05"}]